The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...
Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...
The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...
After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged ...
In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer ...
Families with Huntington’s need this to be true more than most. The devastating neurodegenerative disease is caused by a CAG ...
Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...
The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like ...
Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback